RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease

Neurobiology of Disease

Volumn 70, Issue , 2014, Pages 138-148

  Ko, Wai Kin D ^a,b   Martin Negrier, Marie Laure ^b   Bezard, Erwan ^b   Crossman, Alan R ^a   Ravenscroft, Paula ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Abnormal involuntary movements; Antisense oligonucleotides; L DOPA induced dyskinesia; Parkinson's disease; RGS4

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BENSERAZIDE; DOPAMINE; DOPAMINE RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LEVODOPA; MESSENGER RNA; OXIDOPAMINE; PRODYNORPHIN; RGS4 PROTEIN; ANTIPARKINSON AGENT; ENKEPHALIN; PREPROENKEPHALIN; PROTEIN PRECURSOR; RGS PROTEIN; BENSERAZIDE PLUS LEVODOPA; SULFUR 35;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CORPUS STRIATUM; DYSKINESIA; EX VIVO STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; MALE; NEUROPATHOLOGY; NONHUMAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; CELL CULTURE; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; GENE EXPRESSION; GENE THERAPY; GENETICS; HEMISPHERIC DOMINANCE; METABOLISM; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; UPREGULATION; BEHAVIOR; BRAIN DAMAGE; CONTINUOUS INFUSION; CONTROLLED STUDY; DORSOLATERAL STRIATUM; EMBRYO; IN SITU HYBRIDIZATION; INFUSION; RAT MODEL; RECEPTOR SENSITIVITY; ROSTRAL STRIATUM;

ANIMALS; ANTIPARKINSON AGENTS; CELLS, CULTURED; CORPUS STRIATUM; DYSKINESIA, DRUG-INDUCED; ENKEPHALINS; FUNCTIONAL LATERALITY; GENE EXPRESSION; GENETIC THERAPY; LEVODOPA; MALE; OLIGONUCLEOTIDES, ANTISENSE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PROTEIN PRECURSORS; RATS, SPRAGUE-DAWLEY; RGS PROTEINS; RNA, MESSENGER; UP-REGULATION;

EID: 84904569237     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.06.013     Document Type: Article

References (68)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 2001, 16:448-458.
2. Akhtar S., Kole R., Juliano R.L. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci. 1991, 49:1793-1801.
3. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990, 13:266-271.
4. Andersson M., Hilbertson A., Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6:461-474.
5. Andersson M., Konradi C., Cenci M.A. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J. Neurosci. 2001, 21:9930-9943.
6. Andersson M., Westin J.E., Cenci M.A. Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur. J. Neurosci. 2003, 17:661-666.
7. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., Bioulac B.H., Gross C.E., Fisone G., Bloch B., Bezard E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
8. Aubert I., Guigoni C., Li Q., Dovero S., Bioulac B.H., Gross C.E., Crossman A.R., Bloch B., Bezard E. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry 2007, 61:836-844.
9. Bansal G., Druey K.M., Xie Z. R4 RGS proteins: regulation of G-protein signaling and beyond. Pharmacol. Ther. 2007, 116:473-495.
10. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can. Med. Assoc. J. 1962, 87:802-807.
11. Belujon P., Lodge D.J., Grace A.A. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. Mov. Disord. 2010, 25:1568-1576.
12. Bergquist F., Shahabi H.N., Nissbrandt H. Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod. Brain Res. 2003, 973:81-91.
13. Beyer C.E., Ghavami A., Lin Q., Sung A., Rhodes K.J., Dawson L.A., Schechter L.E., Young K.H. Regulators of G-protein signaling 4: modulation of 5-HT1A-mediated neurotransmitter release in vivo. Brain Res. 2004, 1022:214-220.
14. Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2001, 2:577-588.
15. Bezard E., Munoz A., Tronci E., Pioli E.Y., Li Q., Porras G., Bjorklund A., Carta M. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia. Neurosci. Res. 2013, 77:242-246.
16. Campbell J.M., Bacon T.A., Wickstrom E. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Methods 1990, 20:259-267.
17. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
18. Cenci M.A., Tranberg A., Andersson M., Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-DOPA treatment. Neuroscience 1999, 94:515-527.
19. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998, 50:S17-S25.
20. Chen L., Togasaki D.M., Langston J.W., Di Monte D.A., Quik M. Enhanced striatal opioid receptor-mediated G-protein activation in l-DOPA-treated dyskinetic monkeys. Neuroscience 2005, 132:409-420.
21. Cotzias G.C., Papavasiliou P.S., Gellene R. Modification of Parkinsonism-chronic treatment with l-DOPA. N. Engl. J. Med. 1969, 280:337-345.
22. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179:76-89.
23. Dias N., Stein C.A. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 2002, 1:347-355.
24. Ding J., Guzman J.N., Tkatch T., Chen S., Goldberg J.A., Ebert P.J., Levitt P., Wilson C.J., Hamm H.E., Surmeier D.J. RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat. Neurosci. 2006, 9:832-842.
25. Eder P.S., Devine R.J., Dagle J.M., Walder J.A. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma. Antisense Res. Dev. 1991, 1:141-151.
26. Garzon J., Rodriguez-Diaz M., Lopez-Fando A., Sanchez-Blazquez P. RGS9 proteins facilitate acute tolerance to mu-opioid effects. Eur. J. Neurosci. 2001, 13:801-811.
27. Geurts M., Hermans E., Maloteaux J.M. Opposite modulation of regulators of G protein signalling-2 RGS2 and RGS4 expression by dopamine receptors in the rat striatum. Neurosci. Lett. 2002, 333:146-150.
28. Geurts M., Maloteaux J.M., Hermans E. Altered expression of regulators of G-protein signaling (RGS) mRNAs in the striatum of rats undergoing dopamine depletion. Biochem. Pharmacol. 2003, 66:1163-1170.
29. Gold S.J., Ni Y.G., Dohlman H.G., Nestler E.J. Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain. J. Neurosci. 1997, 17:8024-8037.
30. Gold S.J., Hoang C.V., Potts B.W., Porras G., Pioli E., Kim K.W., Nadjar A., Qin C., Lahoste G.J., Li Q., Bioulac B.H., Waugh J.L., Gurevich E., Neve R.L., Bezard E. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J. Neurosci. 2007, 27:14338-14348.
31. Grillet N., Pattyn A., Contet C., Kieffer B.L., Goridis C., Brunet J.F. Generation and characterization of Rgs4 mutant mice. Mol. Cell. Biol. 2005, 25:4221-4228.
32. He L., Di Monte D.A., Langston J.W., Quik M. Autoradiographic analysis of dopamine receptor-stimulated [(35)S]GTPgammaS binding in rat striatum. Brain Res. 2000, 885:133-136.
33. Henry B., Crossman A.R., Brotchie J.M. Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 1998, 151:334-342.
34. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 1999, 155:204-220.
35. Henry B., Duty S., Fox S.H., Crossman A.R., Brotchie J.M. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol. 2003, 183:458-468.
36. Hepler J.R. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol. Sci. 1999, 20:376-382.
37. Hollinger S., Hepler J.R. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol. Rev. 2002, 54:527-559.
38. Jenner P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 2008, 9:665-677.
39. Johnston T.H., Fox S.H., Mcildowie M.J., Piggott M.J., Brotchie J.M. Reduction of l-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2010, 333:865-873.
40. Kobylecki C., Cenci M.A., Crossman A.R., Ravenscroft P. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. J. Neurochem. 2010, 114:499-511.
41. Lerner T.N., Kreitzer A.C. RGS4 is required for dopaminergic control of striatal LTD and susceptibility to Parkinsonian motor deficits. Neuron 2012, 73:347-359.
42. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
43. Marin C., Rodriguez-Oroz M.C., Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp. Neurol. 2006, 197:269-274.
44. Mcgeorge A.J., Faull R.L. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 1989, 29:503-537.
45. Mela F., Marti M., Dekundy A., Danysz W., Morari M., Cenci M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem. 2007, 101:483-497.
46. Neubig R.R., Siderovski D.P. Regulators of G-protein signalling as new central nervous system drug targets. Nat. Rev. Drug Discov. 2002, 1:187-197.
47. Paspalas C.D., Selemon L.D., Arnsten A.F. Mapping the regulator of G protein signaling 4 (RGS4): presynaptic and postsynaptic substrates for neuroregulation in prefrontal cortex. Cereb. Cortex 2009, 19:2145-2155.
48. Paxinos G., Watson C. The Rat Brain Stereotatic Coordinates 1986, Academic Press, San Diego. 2nd ed.
49. Pepperl D.J., Shah-Basu S., Vanleeuwen D., Granneman J.G., Mackenzie R.G. Regulation of RGS mRNAs by cAMP in PC12 cells. Biochem. Biophys. Res. Commun. 1998, 243:52-55.
50. Porras G., Berthet A., Dehay B., Li Q., Ladepeche L., Normand E., Dovero S., Martinez A., Doudnikoff E., Martin-Negrier M.L., Chuan Q., Bloch B., Choquet D., Boue-Grabot E., Groc L., Bezard E. PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking. J. Clin. Invest. 2012, 122:3977-3989.
51. Rahman Z., Gold S.J., Potenza M.N., Cowan C.W., Ni Y.G., He W., Wensel T.G., Nestler E.J. Cloning and characterization of RGS9-2: a striatal-enriched alternatively spliced product of the RGS9 gene. J. Neurosci. 1999, 19:2016-2026.
52. Rahman Z., Schwarz J., Gold S.J., Zachariou V., Wein M.N., Choi K.H., Kovoor A., Chen C.K., Dileone R.J., Schwarz S.C., Selley D.E., Sim-Selley L.J., Barrot M., Luedtke R.R., Self D., Neve R.L., Lester H.A., Simon M.I., Nestler E.J. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 2003, 38:941-952.
53. Ravenscroft P., Chalon S., Brotchie J.M., Crossman A.R. Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp. Neurol. 2004, 185:36-46.
54. Rylander D., Recchia A., Mela F., Dekundy A., Danysz W., Cenci M.A. Pharmacological modulation of glutamate transmission in a rat model of l-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 2009, 330:227-235.
55. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
56. 2+ channel reduces development of abnormal involuntary movement in the rat model of l-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry 2009, 65:518-526.
57. Schwendt M., Mcginty J.F. Regulator of G-protein signaling 4 interacts with metabotropic glutamate receptor subtype 5 in rat striatum: relevance to amphetamine behavioral sensitization. J. Pharmacol. Exp. Ther. 2007, 323:650-657.
58. Schwendt M., Gold S.J., Mcginty J.F. Acute amphetamine down-regulates RGS4 mRNA and protein expression in rat forebrain: distinct roles of D1 and D2 dopamine receptors. J. Neurochem. 2006, 96:1606-1615.
59. Schwendt M., Sigmon S.A., Mcginty J.F. RGS4 overexpression in the rat dorsal striatum modulates mGluR5- and amphetamine-mediated behavior and signaling. Psychopharmacology (Berlin) 2011, 221:621-635.
60. Sim L.J., Selley D.E., Childers S.R. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7242-7246.
61. 125I]RTI-121. Synapse 1995, 21:364-372.
62. Taymans J.M., Kia H.K., Claes R., Cruz C., Leysen J., Langlois X. Dopamine receptor-mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time. Eur. J. Neurosci. 2004, 19:2249-2260.
63. Tesmer J.J., Berman D.M., Gilman A.G., Sprang S.R. Structure of RGS4 bound to AlF4-activated G(i alpha1): stabilization of the transition state for GTP hydrolysis. Cell 1997, 89:251-261.
64. Voorn P., Vanderschuren L.J., Groenewegen H.J., Robbins T.W., Pennartz C.M. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci. 2004, 27:468-474.
65. Westin J.E., Andersson M., Lundblad M., Cenci M.A. Persistent changes in striatal gene expression induced by long-term l-DOPA treatment in a rat model of Parkinson's disease. Eur. J. Neurosci. 2001, 14:1171-1176.
66. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
67. Yin L.L., Cao Y., Xie K.Q. Decreased RGS9 protein level in the striatum of rodents undergoing MPTP or 6-OHDA neurotoxicity. Neurosci. Lett. 2010, 479:231-235.
68. Zhang D., Zhang L., Tang Y., Zhang Q., Lou D., Sharp F.R., Zhang J., Xu M. Repeated cocaine administration induces gene expression changes through the dopamine D1 receptors. Neuropsychopharmacology 2005, 30:1443-1454.